BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	2,419	2,096	1,846	1,860	1,704
Revenue Growth (YoY)	15.42%	13.53%	-0.76%	9.18%	14.27%
Cost of Revenue	514.85	483.67	470.52	524.27	359.47
Gross Profit	1,904	1,612	1,376	1,336	1,345
Selling, General & Admin	937.29	854.01	759.38	737.67	680.92
Research & Development	746.77	649.61	628.79	628.12	715.01
Other Operating Expenses	62.21	-40.81	69.93	13.84	49.11
Operating Expenses	1,746	1,463	1,458	1,380	1,445
Operating Income	158.1	149.56	-82.34	-43.44	-100.46
Interest Expense / Income	17.34	15.97	15.34	29.31	23.46
Other Expense / Income	-47.8	-15.98	-22.33	-23.75	-29.11
Pretax Income	188.56	149.58	-75.35	-49	-94.81
Income Tax	20.92	8.02	-11.27	-903.03	-70.96
Net Income	167.65	141.56	-64.08	854.03	-23.85
Net Income Growth	18.43%	-	-	-	-
Shares Outstanding (Basic)	188	185	183	181	179
Shares Outstanding (Diluted)	192	189	183	192	179
Shares Change	1.39%	3.34%	-4.60%	7.06%	1.00%
EPS (Basic)	0.89	0.76	-0.35	4.72	-0.13
EPS (Diluted)	0.87	0.75	-0.35	4.50	-0.13
EPS Growth	16.00%	-	-	-	-
Free Cash Flow	62.57	158.27	208.96	38.21	-71.76
Free Cash Flow Per Share	0.33	0.85	1.14	0.21	-0.40
Gross Margin	78.72%	76.92%	74.52%	71.82%	78.91%
Operating Margin	6.54%	7.14%	-4.46%	-2.33%	-5.90%
Profit Margin	6.93%	6.75%	-3.47%	45.90%	-1.40%
Free Cash Flow Margin	2.59%	7.55%	11.32%	2.05%	-4.21%
Effective Tax Rate	11.09%	5.36%	-	-	-
EBITDA	310.28	267.52	48.03	85.48	33.95
EBITDA Margin	12.83%	12.76%	2.60%	4.59%	1.99%
Depreciation & Amortization	104.39	101.97	108.04	105.17	105.3
EBIT	205.9	165.55	-60.01	-19.69	-71.35
EBIT Margin	8.51%	7.90%	-3.25%	-1.06%	-4.19%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).